Anbio Biotechnology NNNN
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.15
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8.6M | $8.2M | $6.7M | $23.5M | — |
| Cost of revenue | $1.1M | $2.3M | $3.4M | $11.0M | — |
| Gross profit | $7.5M | $5.9M | $3.4M | $12.6M | — |
| R&D | $201.3K | $454.2K | $134.7K | $200.0K | — |
| SG&A | $1.6M | $3.4M | $1.3M | $2.2M | — |
| Total operating expenses | $1.8M | $3.9M | $1.4M | $2.4M | — |
| Operating income | $5.8M | $2.0M | $2.0M | $10.2M | — |
| Interest expense | — | — | — | $8.0K | — |
| Pre-tax income | $6.4M | $2.4M | $2.3M | $10.0M | — |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | $6.4M | $2.4M | $2.3M | $10.0M | — |
| EPS, basic | 0.15 | 0.06 | 0.10 | 100,112.00 | — |
| EPS, diluted | 0.15 | 0.06 | 0.10 | 100,112.00 | — |
| Shares, diluted (wtd. avg.) | 43.7M | 42.3M | 21.4M | 100 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $7.8M | $11.8M | $9.7M | $7.1M | $4.2M |
| Short-term investments | $4.1M | $0 | — | — | — |
| Receivables | $3.7M | $1.1M | $1.9M | — | — |
| Total current assets | $30.2M | $18.5M | $15.7M | — | — |
| Total assets | $30.2M | $18.9M | $15.8M | — | — |
| Accounts payable | $0 | $1.6M | $827.2K | — | — |
| Total current liabilities | $87.8K | $1.7M | $993.1K | — | — |
| Total liabilities | $87.8K | $1.7M | $993.1K | — | — |
| Retained earnings | $23.6M | $17.2M | $14.8M | — | — |
| Total equity | $30.2M | $17.2M | $14.8M | $12.5M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$6.7M | $2.1M | $898.4K | $4.4M | — |
| Investing cash flow | -$4.2M | $337.1K | $1.7M | -$1.5M | — |
| Financing cash flow | $6.9M | -$344.6K | -$42.8K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001185185-26-001294.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $23.5M | $6.7M | $8.2M | $8.6M |
| Gross profit | — | $12.6M | $3.4M | $5.9M | $7.5M |
| Net income | — | $10.0M | $2.3M | $2.4M | $6.4M |
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |